Luton J P, Mahoudeau J A, Bouchard P, Thieblot P, Hautecouverture M, Simon D, Laudat M H, Touitou Y, Bricaire H
N Engl J Med. 1979 Mar 1;300(9):459-64. doi: 10.1056/NEJM197903013000903.
In a study of nonsurgical therapy of Cushing's disease, 62 patients received O,p'-dichlorodiphenyldichloroethane (O,p'DDD), 16 of whom also received cobalt irradiation of the pituitary. After an initial treatment period averaging eight months, a remission of the disease was obtained in 38 of the 46 patients given O,p'DDD alone and in all patients who received drug combined with radiation. Although 60 per cent of these patients subsequently relapsed, additional courses of drug or radiation therapy were usually effective, and 63 per cent of the entire group of patients have so far been kept under control without adrenalectomy. (Forty patients have been followed for at least two years after the initial course of treatment.). O,p'DDD produced little gastrointestinal discomfort; an increased serum cholesterol was the main side effect. This drug allows long-term medical management of Cushings disease in most cases. Whether the combination of O'p'DDD with pituitary radiation is the best therapy has not been established.
在一项库欣病非手术治疗的研究中,62例患者接受了邻对滴滴滴(O,p'-二氯二苯二氯乙烷)治疗,其中16例还接受了垂体钴照射。在平均为期8个月的初始治疗期后,仅接受邻对滴滴滴治疗的46例患者中有38例病情缓解,接受药物联合放疗的所有患者病情均得到缓解。尽管这些患者中有60%随后复发,但额外的药物或放疗疗程通常有效,迄今为止,整个患者组中有63%在未进行肾上腺切除术的情况下病情得到控制。(40例患者在初始疗程后至少随访了两年。)邻对滴滴滴几乎未引起胃肠道不适;血清胆固醇升高是主要副作用。在大多数情况下,这种药物可实现库欣病的长期药物治疗。邻对滴滴滴与垂体放疗联合是否为最佳治疗方案尚未确定。